While Sox2, Oct4, and Nanog are transcription factors that are notoriously difficult to block with small molecule inhibitors, focusing on inhibiting Lin28 to prevent its binding to RNA substrates emerges as an attractive strategy for cancer therapy [5, 6]. This evidence concerns the gene POU5F1 and cancer.